Placental vasculogenesis and angiogenesis in women undergoing chemotherapy
DOI: 10.32364/2618-8430-2021-4-1-23-30
Yu.E. Dobrokhotova1, E.I. Borovkova1, A.M. Arutyunyan1, S.Zh. Danelyan2, E.M. Malysheva2, N.V. Zharkov2,3, T.N. Aksenova2
1 Pirogov Russian National Research Medical University, Moscow, Russian Federation
2City Clinical Hospital No. 40, Moscow, Russian Federation
3 I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow,
Russian Federation
Aim: to study placental vasculogenesis and angiogenesis in women receiving chemotherapy.
Patients and Methods: placental structure was examined in 57 pregnant women aged 22–38 years who were subdivided into 3 groups, i.e., women with malignancies receiving or not receiving chemotherapy and healthy controls. The slices of the central part of placentas collected after childbirth were examined. Immunohistochemistry (IHC) was performed after standard histology. IHC intensity was assessed for CD31 and CD34. In addition to IHC intensity, the number of positive cells per field of view was calculated for VEGF, VEGFR1, and VEGFR2. Mean counts of positive cells separately for epithelial and stromal cells were calculated for eNOS.
Results: in the control group, the maturity of the placental villous tree matched the gestational age. Meanwhile, in 100% of pregnant women with malignancies receiving chemotherapy and in 46.8% of pregnant women with malignancies not receiving chemot herapy, the maturity of the placental villous tree was 2–4 weeks behind the gestational age. IHC revealed no significant differences in the placental concentrations of CD31, CD39, eNOS, VEGF, VEGFR1, and VEGFR2 between women with malignancies not receiving chemotherapy and the controls. In women receiving chemotherapy, IHC intensity and the number of positive cells were twice as high as in the control group. The activity of VEGFR1 and VEGFR2 was 11 times higher and 1.4 times higher, respectively, than in the control group. The mean number of cells expressing VEGFR1 and VEGFR2 per field of view increased by 1.5 times and 1.7 times, respectively. In addition, 1.6-fold reduction in CD31 level and 1.3-fold reduction in CD34 level as well as 1.4-fold increase in epithelial еNOS level and 1.3-fold increase in stromal eNOS level were revealed.
Conclusions: our findings on IHC distribution of the expression of VEGF and its recep-tors in the placental tissue of pregnant women undergoing cytostatic chemotherapy in part illus-trate the processes of the compensation and impaired functioning of the mother-placenta-fetus system in pre-placental hypoxia.
Keywords: angiogenesis, vasculogenesis, vascular growth factor, chemotherapy, hypoxia, placental insufficiency.
For citation: Yu.E. Dobrokhotova, Borovkova E.I., Arutyunyan A.M., Danelyan S.Zh. et al. Placental vasculogenesis and angiogenesis in women undergoing chemotherapy. Russian Journal of Woman and Child Health. 2021;4(1):23–30. DOI: 10.32364/2618-8430-2021-4-1-23-30.
2. Sokolov D.I. Vasculogenesis and angiogenesis in development of a placenta. Journal of Obstetrics and Women`s Diseases. 2007;56(3):129–133 (in Russ.).
3. Demir R. Expression of VEGF receptors VEFGR-1 and VEGFR-2, angiopoietin receptors Tie-1 and Tie-2 in chorionic villi tree during early pregnancy. Folia Histochem Cytobiol. 2009;47(3):435–445. DOI: 10.2478/v10042-009-0100-5.
4. Qin Liu, Tao Yin, Guoping Wang et al. Vascular endothelial growth receptor 1 acts as a stress-associated protein in the therapeutic response to thalidomide. Exp Ther Med. 2017;14:4263–4271. DOI: 10.3892/etm.2017.5028.
5. Seo-Ho Lee, Byung-Ju Kim, Uh-Hyun Kim. The critical role of uterine CD31 as a post-progesterone signal in early pregnancy. Reproduction. 2017;154:595–605. DOI: 10.1530/REP-17-0419.
6. Kulandavelu S., Whiteley K.J., Bainbridge S.A. et al. Endothelial NO synthase augments fetoplacental blood flow, placental vascularization, and fetal growth in mice. Hypertension. 2013;61:259–266. DOI: 10.1161/HYPERTENSIONAHA.112.201996.
7. Zubzhitskaya L.B., Kosheleva N.G., Shapovalova E.A. et al. Status of placental barrier of women at the influence of exogenous and endogenous factors. Journal of Obstetrics and Women`s Diseases. 2015;64(5):36–47 (in Russ.).
8. Gardner V., Madu C.O., Lu Y. Anti-VEGF therapy in cancer: a double-edged sword. Intech open science, 2017, chapter 19, 385–410. DOI: 10.5772/66763.
9. Al-Hijji J., Andolf E., Laurini R., Batra S. Nitric oxide synthase activity in human trophoblast, term placenta and pregnant myometrium. Reprod Biol Endocrinol. 2003;1(1):51. DOI: 10.1186/1477-7827-1-51.
10. Manolea M.M., Gavrila O.A., Popescu F.C., Novac L. The importance of immunohistochemical evaluation of the vascular changes from the decidua and placenta in recurrent pregnancy loss. Rom J Morphol Embryol. 2012;53(2):363–368.
11. Min-cheol Kang, Seo Jin Park, Hei Jung Kim et al. Gestational loss and growth restriction by angiogenic defects in placental growth factor transgenic mice. Arterioscler Thromb Vasc Biol. 2014;34:2276–2282. DOI: 10.1161/ATVBAHA.114.303693.
12. Krause B.J., Hanson M.A., Casanello P. Role of nitric oxide in placental vascular development and function. Placenta. 2011;32:797–805. DOI: 10.1016/j.placenta.2011.06.025.
13. Helske S., Vuorela P., Carpen O. et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod. 2001;7(2):205–210. DOI: 10.1093/molehr/7.2.205.
14. Nevo O., Lee D.K., Caniggia I. Attenuation of VEGFR-2 expression by sFlt-1 and low oxygen in human placenta. Plos One. 2013;8(11):e81176. DOI: 10.1371/journal.pone.0081176.
15. Ramırez-Velez R., Bustamante J., Czerniczyniec A. et al. Effect of exercise training on eNOS expression, NO production and oxygen metabolism in human placenta. PLoS One. 2013;8(11):e80225. DOI: 10.1371/journal.pone.0080225.
16. Mackiewicz Z., Dudek E., Glab G. et al. CD34 stem cells in normal placenta tissues and in placenta with intrauterine growth retardation. Acta medica lituanica. 2004;11(2):34–38.
17. Lysyak D.S., Volkova N.N. Pathophysiological mechanisms of placental insufficiency. Far East Medical Journal. 2012;4:134–137 (in Russ.).
18. Sheppard C., Shaw C.E., Li Y. Endothelium-derived nitric oxide synthase protein expression in ovine placental arteries. Biol Reprod. 2001;64:1494–1499. DOI: 10.1095/biolreprod64.5.1494.
19. Volkova E.V., Kopylova Yu.V. The role of vascular growth factors in the pathogenesis of placental insufficiency. Obstetrics, gynecology and reproduction. 2013;7(2):29–33 (in Russ.).
20. Sokolov D.I., Kolobov A.V., Lesnichiya M.V. et al. Role of pro- and antiangiogenic factors in placental development. Medical immunology. 2008;10(4–5):347–352 (in Russ.).
21. Daenen L.G.M., Roodhart J.M.L., van Amersfoort M. et al. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res. 2011;71(22):6976–6985. DOI: 10.1158/0008-5472.CAN-11-0627.
22. Dong-bao Chen, Jing Zheng. Regulation of placental angiogenesis. Manuscript 2013. DOI: 10.1111/micc.12093.
23. Robin C., Bollerot K., Mendes S. et al. Human placenta is a potent hematopoietic niche containing hematopoietic stem and progenitor cells throughout development. Cell Stem Cell. 2009;5(4):385–395. DOI: 10.1016/j.stem.2009.08.020.
24. Ul`yanina E.V., Fatkullin I.F. Vascular endothelial growth factor role in predicting vascular disorders in pregnant with fetal growth restriction syndrome. Kazan medical journal. 2015;96(2):220–223 (in Russ.).
25. Fedorova M.V., Smirnova T.L. Immunohistochemical differences in the placentas of prolonged and the true post-term pregnancy. Bulletin of the Chuvash University. 2013;3:560–563 (in Russ.).
26. Nefedova N.A., Kharlova O.A., Danilova N.V. et al. Markers of angiogenesis in tumor growth. Archive of pathology. 2016;2:55–62 (in Russ.).
27. Dobrokhotova Yu.E., Borovkova E.I., Arutyunyan A.M. Breast cancer associated with pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2019;19(4):77–81 (in Russ.).
28. Dobrokhotova Yu.E., Borovkova E.I., Zalesskaya S.A. et al. Chemotherapy during pregnancy: opportunities and risks. Russian bulletin of obstetrician-gynecologist. 2019;19(3):81–85 (in Russ.).
29. Dobrokhotova Yu.E., Borovkova E.I. Obstetric risks of chemotherapy during pregnancy. Gynecology. 2018;6:16–19 (in Russ.).
30. Malamitsi-Puchner A., Boutsikou T., Economou E. et al. Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm. 2005;2005(5):293–297. DOI: 10.1155/MI.2005.293.
31. Arutyunyan I.V., Kananykhina E. Yu., Makarov A.V. Role of VEGF-А165 receptors in angiogenesis. Cellular transplantation and tissue engineering. 2013;VIII(1):12–18 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
